Adults with type 1 diabetes who are already on insulin pump therapy but have not achieved the targeted improvement in glycated hemoglobin (A1C) may require an escalation in strategy — particularly when nocturnal hypoglycemia remains a significant concern.
Continuous subcutaneous insulin infusion (CSII; insulin pump therapy), used with or without continuous glucose monitoring (CGM), was the prior line of treatment. The expected clinical goal — improvement in A1C — was not achieved, indicating the need to move to a more advanced approach.
The next step centres on a form of sensor-augmented pump therapy that incorporates an automated protective function for critically low glucose levels. The complete protocol specifies how this approach is configured and applied — see the full regimen for details.
Reduction in nocturnal hypoglycemia.
DOI: 10.1016/j.jcjd.2017.10.012